Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
76.6M
-
Number of holders
-
64
-
Total 13F shares, excl. options
-
31.9M
-
Shares change
-
+31.9M
-
Total reported value, excl. options
-
$1.11B
-
Value change
-
+$1.11B
-
Number of buys
-
64
-
Price
-
$34.91
Significant Holders of Nurix Therapeutics, Inc. - Common Stock (NRIX) as of Q3 2020
64 filings reported holding NRIX - Nurix Therapeutics, Inc. - Common Stock as of Q3 2020.
Nurix Therapeutics, Inc. - Common Stock (NRIX) has 64 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.9M shares
of 76.6M outstanding shares and own 41.57% of the company stock.
Largest 10 shareholders include Svennilson Peter (6.76M shares), TRV GP III, LLC (5.42M shares), WELLINGTON MANAGEMENT GROUP LLP (3.37M shares), Redmile Group, LLC (2.59M shares), Foresite Capital Management IV, LLC (2.35M shares), BAKER BROS. ADVISORS LP (1.79M shares), BOXER CAPITAL, LLC (1.35M shares), Bain Capital Life Sciences Investors, LLC (1.28M shares), EcoR1 Capital, LLC (1.19M shares), and BlackRock Inc. (670K shares).
This table shows the top 64 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.